Johnson & Johnson (JNJ) Holdings Trimmed by Cibc Bank USA

Cibc Bank USA lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,093 shares of the company’s stock after selling 2,120 shares during the quarter. Johnson & Johnson comprises 0.5% of Cibc Bank USA’s portfolio, making the stock its 26th largest holding. Cibc Bank USA’s holdings in Johnson & Johnson were worth $3,785,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the business. Landmark Financial Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after purchasing an additional 7 shares in the last quarter. Paradigm Financial Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock worth $350,000 after purchasing an additional 9 shares in the last quarter. Premier Asset Management LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after purchasing an additional 12 shares in the last quarter. Lbmc Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after purchasing an additional 14 shares in the last quarter. Finally, Halbert Hargrove Russell LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after purchasing an additional 15 shares in the last quarter. 67.23% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of JNJ stock opened at $128.10 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The company has a market capitalization of $349,877.28, a price-to-earnings ratio of 17.55, a P/E/G ratio of 2.07 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the previous year, the company posted $1.58 earnings per share. The business’s revenue was up 11.5% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 8.11 EPS for the current year.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.22% of the company’s stock.

JNJ has been the subject of several recent analyst reports. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 price objective for the company in a report on Thursday. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. Stifel Nicolaus boosted their target price on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Wells Fargo restated an “outperform” rating and issued a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $144.58.

ILLEGAL ACTIVITY NOTICE: This article was published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3337269/johnson-johnson-jnj-holdings-trimmed-by-cibc-bank-usa.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Blue Nile  Earning Somewhat Positive Media Coverage, Analysis Finds
Blue Nile Earning Somewhat Positive Media Coverage, Analysis Finds
SwissBorg Market Capitalization Tops $18.31 Million
SwissBorg Market Capitalization Tops $18.31 Million
EchoLink  Reaches 24 Hour Trading Volume of $3.95 Million
EchoLink Reaches 24 Hour Trading Volume of $3.95 Million
Reviewing Nymox Pharmaceutical  & Quidel
Reviewing Nymox Pharmaceutical & Quidel
Sallie Mae  Expected to Post Quarterly Sales of $315.09 Million
Sallie Mae Expected to Post Quarterly Sales of $315.09 Million
Analysts Anticipate IMAX Co.  Will Post Quarterly Sales of $82.09 Million
Analysts Anticipate IMAX Co. Will Post Quarterly Sales of $82.09 Million


Leave a Reply

© 2006-2018 Ticker Report. Google+.